An Anecdotal Studyof Low Dose Naltrexone

Skip Lenz Pharm.D. F.A.S.C.P.with Research Assistants

Shanna Chambliss Pharm.D. (Candidate) University of FloridaVinay Patel Pharm.D. (Candidate) University of Florida

Bandar Saleh Pharm.D. (Candidate) P.B.A. School of PharmacyJeremy Thomas Pharm.D. (Candidate) University of Florida

Hew Fong Pharm.D. (Candidate) University of FloridaFelicia Fong Kong Pharm.D. (Candidate) University of Florida

Skip’s PharmacyBoca Raton, Fl.

Demographics

• Number of patients surveyed: 242 (p=v0.5)• Number of patients with diagnosis of MS: 207 (as reported by patients)

• Chronic progressive: 8 (4%)• Primary progressive: 13 (6%)• Secondary progressive: 35 (17%)• Relapse remitting: 79 (38%)• Unknown: 72 (35%)

• Number of Patients with diagnosis other then MS: 35 (as reported bypatients)• Cancer: 13• Fibromyalgia: 5• Neuropathy: 3• Prophylaxis: 3• Other: 11

• Time Period Represented: 12/01/00 - 06/30/05

Questionnaire1. What is the reason (your diagnosis) for taking LDN

2. How long have you had this condition/disease

3. (if the diagnosis is Multiple Sclerosis) -Is the Condition type progressive or relapse/remitting? Or other

4. (if relapse remitting MS)When was your last exacerbation?

5. How would you rate your symptoms after starting LDN vs. beforeLDN

a) Worsened b) No Change c) Improved

6. How long did it take for you to see a change in your symptomssince you started LDN?

Types of MS Reported by Patients

Primary ProgressiveSecondary ProgressiveRelapse RemittingChronic ProgressiveUnknown by Patient

Overall Results After TakingLDN

ImprovedNo ChangeWorsened

Relapse Remitting Results

ImprovedNo ChangeWorsenedMixed

3(4%)

1(1%)

Unknown by Patient Results

ImprovedNo ChangeWorsened

Primary Progressive Results

No ChangeImproved

Secondary Progressive Results

ImprovedNo ChangeWorsened

Chronic Progressive Results

ImprovedNo ChangeMixed

Days To Results Versus Number ofYears with Diagnosis

% Improvement Based onType of Drug Therapy

% Improvement Based on type of DrugTherapy in Relapse Remitting MS

Citations

www.avonex.comwww.rebif.comwww.betaseron.comwww.popaxone.comwww.novantrone.com

Goodin, D.S. "Disease ModifyingTherapy in Multiple Sclerosis”Report of the Therapeutic andTechnology AssessmentSubcommittee of the AmericanAcademy of Neurology and the MSCouncil for Clinical PracticeGuidelines. Neurology #58 Jan2002 pg. 169-178

Goodin, D.S. "The Use of Mitoxantrone(novantrone) for the treatment ofMultiple Sclerosis" Report of theTherapeutic and TechnologyAssessment Subcommittee of theAmerican Academy of Neurology.Neurology #61 Nov. 2003 pg. 1332-1338